Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NFH0R4ZHfW6ldHnvckBCe3OjeR?= MorkNE42yqEQvF2= M{HyVFI1KGh? NFHYUY94[XSnch?= NHHrdoJud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? M4jLXVI2OTJ|MEiy
Eca109 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyzXIExNjVxMj61M|Uh|ryP MXiyOE81QC95MjDo NUDjbGxlf2G2ZYK= MmHLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= NFjSSXQzPTF{M{C4Ni=>
Eca109 MnXvSpVv[3Srb36gRZN{[Xl? Ml7QNE42yqEQvF2= NWPwWpN6Pi9zMj:yOEBp MXf3ZZRmeg>? M3PPbolvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= M{nY[FI2OTJ|MEiy
Eca109 NHvwT5NHfW6ldHnvckBCe3OjeR?= MYmwMlXDqM7:TR?= MlPQNlQhcA>? NH;me5R4[XSnch?= Mk\1bY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MYiyOVEzOzB6Mh?=
Eca109 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DPU|AvPcLizszN NVTmNpprOjRiaB?= NITKRnR4[XSnch?= NILNcG5qdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm MVeyOVEzOzB6Mh?=
Eca109 MoHhSpVv[3Srb36gRZN{[Xl? NWjSdZdOOC53L{Gg{txO NF3Q[HAzPCCq NIn0O5F4[XSnch?= MVrk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz Ml\INlUyOjNyOEK=
SW1116  M1\k[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETlWmIxNjVxMT:yM|Uh|ryP NX2zS3JzPDhiaB?= M4qzb2ROW09? MXvlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NI\sN3MzPDh5NEK4Oi=>
LOVO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17OUFAvPS9zL{KvOUDPxE1? NVr6fGxCPDhiaB?= MWrEUXNQ NHnLVnpmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NFSxeVMzPDh5NEK4Oi=>
SW1116  MnPmSpVv[3Srb36gRZN{[Xl? MWqxNEDPxE1? NHXjN4c1QCCq M4foN2ROW09? MWPpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NX:3T2M6OjR6N{SyPFY>
LOVO MV\GeY5kfGmxbjDBd5NigQ>? M3K1TlExKM7:TR?= NF;WZlM1QCCq NFHoTVVFVVOR NX;nfYJycW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk M2n5VFI1QDd2Mki2
SW1116  Mn;ZRZBweHSxc3nzJGF{e2G7 NE\HXXgyOCEQvF2= MoDNOFghcA>? MUHEUXNQ M1nUd4VvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> M1e0NFI1QDd2Mki2
LOVO MX\BdI9xfG:|aYOgRZN{[Xl? MoPlNVAh|ryP NITH[Gc1QCCq MnjJSG1UVw>? MULlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NYPEeWh7OjR6N{SyPFY>
RPMI-8226 MXHBdI9xfG:|aYOgRZN{[Xl? MVOxM|Ih|ryP NGDFNJk1QC95Mj:5OkBp M1zkSGROW09? NV32R|c5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MljQNlQ5OzNzMEi=
OPM-2  NESx[FNCeG:ydH;zbZMhSXO|YYm= M{fXN|EwOiEQvF2= NGHH[XA4Oi97Nj:xNlAhcA>? MkPMSG1UVw>? NFnwZmJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUDOeIFUOjR6M{OxNFg>
JJN3  NXfVOGFQSXCxcITvd4l{KEG|c3H5 M{DDUVAvPS9zIN88US=> NVT3NmFsOjRxNEigbC=> NX\PTGFJTE2VTx?= MVvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnLnNlQ5OzNzMEi=
NCI-H929  MmP6RZBweHSxc3nzJGF{e2G7 NFjsfXMyNzJizszN NHXESno4Oi97Nj:xNlAhcA>? NETNUmZFVVOR Mne3bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MX6yOFg{OzFyOB?=
RPMI-8226 M{TLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\PWoFzOS9{IN88US=> M{\oflI1NzR6L{eyJIg> MYHEUXNQ MmL2ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M1PBXFI1QDN|MUC4
OPM-2  NILwOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13iTVEwOiEQvF2= NFnONFczPC92OD:3NkBp NUnuTm9iTE2VTx?= NVr5[2tj[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M2q5NVI1QDN|MUC4
JJN3  M2fSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMlUwOSEQvF2= MoLlNlQwPDhxN{KgbC=> M2i2TmROW09? M2DRTYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MUmyOFg{OzFyOB?=
NCI-H929  NHnYOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PJZ|EwOiEQvF2= NU\XXIdJOjRxNEivO|IhcA>? NWnO[HE3TE2VTx?= MoS2ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NYfxcZY4OjR6M{OxNFg>
HeLa M2K1RmtqdmG|ZTDBd5NigQ>? MYXLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx MkL1NlQ4QDByOUi=
HeLa NH\vfoRMcW6jc3WgRZN{[Xl? MX\LbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK= MUCyOFc5ODB7OB?=
HeLa NUjybVFVU2mwYYPlJGF{e2G7 NFfJTFBMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy M3nFdlI1PzhyMEm4
HeLa MWfLbY5ie2ViQYPzZZk> MWTLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz Mn\wNlQ4QDByOUi=
NB4 NVHYS4YyTnWwY4Tpc44hSXO|YYm= NXHXems5Oi53L{WvO{42NzFyIN88US=> NHn3Um8zPCCq MmDXSG1UVw>? MnXlbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> NUCw[oZEOjR2OES4O|A>
CD4+ CD25− T  MXTGeY5kfGmxbjDBd5NigQ>? MYixM|Uh|ryP Mnj3doVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v M{jOOVI1PDd4M{[w
BV-173 MoPsRZBweHSxc3nzJGF{e2G7 NFm1[|UxNjJ3L{CuOU8xNjd3L{Gg{txO MYG0PE84Oi97NjDo MnuyxsBRSlN? MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M{fheVI1PDJ|NkGz
ML-1 MW\BdI9xfG:|aYOgRZN{[Xl? NHTN[W0xNjJ3L{CuOU8xNjd3L{Gg{txO NFztTpk1QC95Mj:5OkBp MonOxsBRSlN? M3m1b4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MnnBNlQ1OjN4MUO=
HL-60 M2X2N2Fxd3C2b4Ppd{BCe3OjeR?= MoTSNE4zPS9yLkWvNE44PS9zIN88US=> Mo[zOFgwPzJxOU[gbC=> MYJCpHBDWw>? MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MUWyOFQzOzZzMx?=
KG-1a M1XD[GFxd3C2b4Ppd{BCe3OjeR?= MlLlNE4zPS9yLkWvNE44PS9zIN88US=> NGWwXHk1QC95Mj:5OkBp M3r1R:KhWEKV NXT0OmRTcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NFn4fWMzPDR{M{[xNy=>
BV-173 M{XWUmZ2dmO2aX;uJGF{e2G7 MWmyOVAwPTBybl2= NETLdZI1QCCq M2nLceKhWEKV NYnB[2Q2cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NXvXOJBIOjR2MkO2NVM>
CEM NH7rU3lHfW6ldHnvckBCe3OjeR?= MXKyOVAwPTBybl2= NHfTR5M1QCCq MX|CpHBDWw>? M2G2O4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M2DuO|I1PDJ|NkGz
HL-60 MY\GeY5kfGmxbjDBd5NigQ>? NGDWOmczPTBxNUCwcm0> M2DnbVQ5KGh? M1K5WuKhWEKV NGf6T|BqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NIHqWpgzPDR{M{[xNy=>
ML-1 MkDySpVv[3Srb36gRZN{[Xl? M4T1T|I2OC93MEDuUS=> MmDoOFghcA>? NHnNUWHDqFCEUx?= NHnJ[YFqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= MkTKNlQ1OjN4MUO=
DLD-1 M{\mV2Z2dmO2aX;uJGF{e2G7 MWKyOVAwPTBybl2= Mo\oOFghcA>? NYC5VWNxyqCSQmO= MWrkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NYjiNFNiOjR2MkO2NVM>
HCT-116 NE\TRmVHfW6ldHnvckBCe3OjeR?= NWjiZmREOjVyL{WwNI5O NEDxTpI1QCCq M4X3TeKhWEKV Mmrn[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MmrjNlQ1OjN4MUO=
U937-A/E-9/14/18  Mon0RZBweHSxc3nzJGF{e2G7 MYGwMlAyNzBwMT:xM|ExKM7:TR?= MVW0PEBp NWPNOYFvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NELJcWgzPDNyMES1Oi=>
HT29 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPYUmUzPzJiaB?= MoTzTWM2OD1zNECwxtEyPzlizszN M{TVXFI1OTd{ME[x
SW48 M3nGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\6O|IhcA>? MljoTWM2OD1zNT6yxtE3NjJizszN NHnRPYMzPDF5MkC2NS=>
HCT116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{na[|czKGh? MlXpTWM2OD1zLkhCtVAvPCEQvF2= M2HVTlI1OTd{ME[x
HepG2 MoDPSpVv[3Srb36gRZN{[Xl? Mn;NNE42NzFizszN M2P3eVI1KGh? MlywSG1UVw>? MmfVeZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NUPIUmF2OjRzNE[4O|Q>
LS174T MlvLSpVv[3Srb36gRZN{[Xl? NGPxR44xNjVxMTFOwG0> NI[wb2EzPCCq MYnEUXNQ MV\s[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= MUiyOFE1Pjh5NB?=
HepG2 NWHDfpp6SXCxcITvd4l{KEG|c3H5 M{iyZlEwOTBxMUCwJO69VQ>? NILCOYM4KGR? NGn6fGRFVVOR MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXTGOVNNOjRzNE[4O|Q>
LS174T NF2y[WpCeG:ydH;zbZMhSXO|YYm= M4O5cVEwOTBxMUCwJO69VQ>? MnXwO{Bl MojiSG1UVw>? NWPVNJB3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFfhXHAzPDF2Nki3OC=>
QBC-939 NUTvRnJGSXCxcITvd4l{KEG|c3H5 NGfNSFkyNzFyL{GwNEDPxE1? MY[3JIQ> MnjlSG1UVw>? MkLDbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUT1T204OjRzNE[4O|Q>
U251 MX3BdI9xfG:|aYOgRZN{[Xl? MYOxM|ExNzFyMDFOwG0> M3TGUVch\A>? M1XWUmROW09? NGXTXYlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXrNPYtEOjRzNE[4O|Q>
HL-60 NULSUIhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXmXoV7OSEQvF2= MWC0PEBp MlmwbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? NFjXWZEzPDByMEOyOC=>
MDA‑MB‑453 MYDGeY5kfGmxbjDBd5NigQ>? MonBNE4zNzFizszN MmDmO|IhcA>? NYqyVYdn[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MUmyN|g1PDJ{OB?=
HCC1569 MoXaSpVv[3Srb36gRZN{[Xl? M3jxcFAvOi9zIN88US=> NUDZUI5iPzJiaB?= M4Pp[oNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MWqyN|g1PDJ{OB?=
BT‑474 NU\HdVhQTnWwY4Tpc44hSXO|YYm= Mkn4NE4zNzFizszN MWK3NkBp NFrwfmZk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NUfES4pCOjN6NESyNlg>
AGS MnP5RZBweHSxc3nzJGF{e2G7 MYq1M|ExNzJyL{WwJO69VQ>? M{\MTlQ5yqCqwrC= MXTEUXNQ NYXnN3NucW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? M1LtUlI{PTh{N{i0
A549 MnTWRZBweHSxc3nzJGF{e2G7 M3nvXVUwOTBxMkCvOVAh|ryP MW[0POKhcMLi NIX3W2FFVVOR MojQbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MkLqNlM2QDJ5OES=
AGS  NYH2UoQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK1M|ExNzJyL{WwJO69VQ>? MV20POKhcMLi NG\vZ4tFVVOR MonWbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg MkLhNlM2QDJ5OES=
Kasumi-1 NIfBXYRCeG:ydH;zbZMhSXO|YYm= M2OzbFAvPSEQvF2= NEXwN5c1QMLiaNMg MkjP[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= Mm\ENlM1QTN|NEi=
OCI-AML3 NVvFZoR6SXCxcITvd4l{KEG|c3H5 MX6yMlUh|ryP NGqycWs1QMLiaNMg M{LRbIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NF\R[FIzOzR7M{O0PC=>
MV4-11 Mn2xRZBweHSxc3nzJGF{e2G7 MXSyMlUh|ryP MmPGOFjDqGkEoB?= NHnnbIRl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MoLtNlM1QTN|NEi=
NK  NHPDWoFEgXSxdH;4bZR6KEG|c3H5 M17xZVAvODJvMkCg{txO NEDrcYw2KGR? NHTBTZdl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n MVuyN|MzQDB6OB?=
NK  Mkn0RZBweHSxc3nzJGF{e2G7 NXTs[mNwOC5yMj2yNEDPxE1? M3LWfVUh\A>? MojU[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl NV63e25JOjN|MkiwPFg>
NK  MXXGeY5kfGmxbjDBd5NigQ>? NUfoXXI1OC5yMT2yNEDPxE1? M17oVlUh\A>? NFjrfGJk[XW|ZYOgbJlxd22ndHj5cIF1cW:wIH;mJG5MKGOnbHzzJIlvKGFiZH;z[gKBm3Knc4DvcpNm NI\WZW8zOzN{OEC4PC=>
MOLT4/DNR M2m5cmZ2dmO2aX;uJGF{e2G7 MnvUOUDPxE1? MmTrOEBl MoPsdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> M3;PclI{ODZyNUew
Jurkat/DOX MnfESpVv[3Srb36gRZN{[Xl? MVm1JO69VQ>? M{CwXVQh\A>? NUG0VYJOemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? NXfo[mV5OjNyNkC1O|A>
MOLT4/DNR M1PPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[1eGJiPSEQvF2= MknkOEBl MXLy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 Mly0NlMxPjB3N{C=
Jurkat/DOX NVvDXZVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW1JO69VQ>? NH3oWHA1KGR? MWXy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MnPTNlMxPjB3N{C=
ccRCC  NES3XnBCeG:ydH;zbZMhSXO|YYm= NH7jfmQxNjBzLUGw{txO NH73VIg4OiCq NYGySJpwTE2VTx?= Ml;nbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MoG1NlI5OjZ2Nke=
TNBC  MWfBdI9xfG:|aYOgRZN{[Xl? NVXCXlFzOC5yMT2xNO69VQ>? MmXsO|IhcA>? Mlf0SG1UVw>? MV7oZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NGfET4QzOjh{NkS2Oy=>
A498 MWnBdI9xfG:|aYOgRZN{[Xl? MmfsNE4xOS1zMN88US=> MXG3NkBp NEnEO4JFVVOR MnvzbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M4\rclIzQDJ4NE[3
KIJ265T NFnpTmtCeG:ydH;zbZMhSXO|YYm= M1SzPVAvODFvMUFOwG0> M3rwUFczKGh? MkCzSG1UVw>? MYjpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MkL4NlI5OjZ2Nke=
MDA-231 M2ruNGFxd3C2b4Ppd{BCe3OjeR?= NFHXOWYxNjBzLUGw{txO MW[3NkBp NVfYOXhLTE2VTx?= NUG3WI9VcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MXGyNlgzPjR4Nx?=
BT-20 Mm[4RZBweHSxc3nzJGF{e2G7 NVX2dIcyOC5yMT2xNO69VQ>? MlvjO|IhcA>? NXj3NlNNTE2VTx?= MWjpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MkfUNlI5OjZ2Nke=
U937 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\2[JQ5PS1{MDFOwG0> MWmyOE81QC95MjDo NFLvcGNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MlXvNlI4PjdyMkG=
HL60 NYH4bVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW1MVIxKM7:TR?= NYqxUW9WOjRxNEivO|IhcA>? NGHBe3ZqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz M3vp[VIzPzZ5MEKx
U937 MlTzRZBweHSxc3nzJGF{e2G7 MYexOUDPxE1? MWeyOE81QC95MjDo Mm\HbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1nMZ|IzPzZ5MEKx
HL60 M3PFU2Fxd3C2b4Ppd{BCe3OjeR?= NXTafFF6OTVizszN Mk\CNlQwPDhxN{KgbC=> NXnKNmFGcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MWCyNlc3PzB{MR?=
LS411N  Ml3mRZBweHSxc3nzJGF{e2G7 M{fWfFAvPSEQvF2= MXO3NkBp MX;pcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? NFi0eoUzOjR4MU[5OS=>
MDA-MB-231 MlXQRZBweHSxc3nzJGF{e2G7 MUmxNEDPxE1? M1PsUFQ5KGh? M1HVNJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mmn5NlE5QDd4OUe=
MCF-7  NHjEUlRCeG:ydH;zbZMhSXO|YYm= NU\0b2pTOTBizszN M2C0bVQ5KGh? NHz0dFRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mnn2NlE5QDd4OUe=
A375 NVrVXnBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLEd3YxNjVizszN NHL1UVQyNzVxODDk MlTNbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NVnGWZVkOjF5OU[2NlI>
SKMEL1 NUnXSZZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrxUGhvOC53IN88US=> MVqxM|UwQCCm NIrtSopqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MUSyNVc6PjZ{Mh?=
SKMEL3 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLkNE42KM7:TR?= NHTvUoIyNzVxODDk M3nDW4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NUnBSXlyOjF5OU[2NlI>
SKMEL28 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMlUh|ryP MoC1NU82NzhiZB?= MkDMbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NF;zW5czOTd7Nk[yNi=>
MeWo NHnHXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYiwMlUh|ryP MWWxM|UwQCCm M17Fc4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MXKyNVc6PjZ{Mh?=
B16 M{DuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LxcVAvPSEQvF2= MYSxM|UwQCCm MlH4bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M3rIc|IyPzl4NkKy
Ly 1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTkbVIzPCCq NH;abZpKSzVyPUeuN{DPxE1? M1fQ[lIyPzd{MES5
Ly 7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO5eVVCOjRiaB?= M2ry[GlEPTB;MUCuO{DPxE1? MnHQNlE4PzJyNEm=
Su-DHL6 NXnsWZQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvjSoYzPCCq NUG3d2dUUUN3MP-8olIxKM7:TR?= NFvLbnQzOTd5MkC0PS=>
Ly 10 NWTVVIwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[yOEBp NIHGUHlKSzVy78{eNlAh|ryP MYiyNVc4OjB2OR?=
RIVA MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGyOEBp NFK4UWlKSzVy78{eNlAh|ryP NWDP[2k4OjF5N{KwOFk>
Su-DHL2 M4K5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnNXW0zOjRiaB?= NH;ZVZJKSzVy78{eNlAh|ryP NYrXfIVKOjF5N{KwOFk>
Ly 1 NULOelViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PLO|Q5KGh? NEHDUJRKSzVyPUCuN|Qh|ryP MUSyNVc4OjB2OR?=
Ly 7 NVzTSGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrRfXE1QCCq MojGTWM2OD1yLkCyOUDPxE1? NInjWoIzOTd5MkC0PS=>
Su-DHL6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK0PEBp MYnJR|Ux97zgMkCg{txO NH3CWVkzOTd5MkC0PS=>
Ly 10 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ntc|Q5KGh? MlXNTWM2OD1zLkig{txO NXjYbIhZOjF5N{KwOFk>
RIVA NHPkb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDad2U1QCCq NFHrS5ZKSzVy78{eNlAh|ryP MkXhNlE4PzJyNEm=
Su-DHL2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPmOFghcA>? M1[5ZWlEPTB;MUeuOEDPxE1? NE\CPIMzOTd5MkC0PS=>
Ly 1 NIjXcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\1W5Q4OiCq MVHJR|UxRTBwMEGg{txO MVmyNVc4OjB2OR?=
Ly 7 NF2zfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli5O|IhcA>? MYXJR|UxRTBwMEG4JO69VQ>? M4DkVlIyPzd{MES5
Su-DHL6 NEfNT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofQO|IhcA>? MmLXTWM2OD1zLk[g{txO MoHpNlE4PzJyNEm=
Ly 10 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLUO|IhcA>? MknOTWM2OD1zLkKg{txO M4fzOFIyPzd{MES5
RIVA NVfqUZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrWdoo4OiCq MnTTTWM2OO,:nkKwJO69VQ>? M4HpbVIyPzd{MES5
Su-DHL2 M4TYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXHUm4{PzJiaB?= M{LOXGlEPTB;MUGuNkDPxE1? NGmxd2kzOTd5MkC0PS=>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

Related Antibodies

DNA Methyltransferase信号経路図

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID